Abstract. Qian HN, Liu GZ, Cao SJ, Feng J, Ye X. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-γ genes.
With the advance of immunology, immunogene therapy is becoming a possible therapeutic alternative to advanced cancer. The aim of tumor immunogene therapy is to enhance the immune response to tumors. Evidence suggests that CD80 (B7-1) and Interferon-gamma (IFN-γ) play important roles in antitumor immunity induced by T lymphocyte. To study the antitumor immune effects of ovarian carcinoma vaccine modified with human B7-1 and IFN-γ genes, we constructed the bicistronic retroviral vector pLXSN, encoding human B7-1 and IFN-γ. In vitro, the primary ovarian carcinoma cells were transduced with the retroviral vector and prepared as a vaccine. Then autologous lymphocytes were irritated with the ovarian carcinoma cells for competition inhibitory cytotoxic testing. The tumor-specific cytotoxic activity was greatly enhanced by the double gene–modified vaccine. In vivo, the tumorigenicity of the double gene–modified ovarian cell line 3AO/B7-1·IFN-γ was evaluated in a human immune reconstituted SCID mice (hu-PBL-SCID) model. The double-gene modification markedly decreases tumor genecity. Together, the results suggest that combining B7-1 and IFN-γ could be a useful therapeutic approach in ovarian cancer.
- ovarian carcinoma vaccine
- retroviral vector
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Supported by a grant from the National Science Foundation of China.